At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses a phase 1b clinical trial that was designed to evaluate the safety and antitumour activity of durvalumab, an anti-PD-L1 antibody, combined with tremelimumab, a CTLA-4 antibody, for the treatment of patients with stage III or IV non-small cell lung cancer.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement